Company intelligence / Profile preview

CarboCode

Cantanhede, Centro Region/Aveiro District, Portugalcarbocode.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CarboCode has developed a proprietary technology enabling the industrial-scale production of human-identical glycosphingolipids and gangliosides. Their first factory can produce up to 100 tons annually. The company aims to supply these ingredients to major infant nutrition companies globally. Regulatory approval processes are underway for key markets with commercial launch expected post-clearance.
No clinical trial results reported as the focus is on ingredient manufacturing rather than therapeutics.

Therapeutic areas: OtherDermatologyGastroenterologyNeurology
Modalities: Glycosphingolipids (including gangliosides)
Industry: Non-Drug Biotech

Partnerships

Targeted B2B supply relationships with Danone, Nestlé, Abbott Laboratories, Mead Johnson Nutrition (planned customers upon regulatory approval)

Beyond the preview

Go deeper on CarboCode.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CarboCode.

Explore the full profile